Category: Business

ORLANDO, FL / ACCESS Newswire / June 6, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Liberty Star Minerals (OTCQB:LBSR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, June 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• SXTP:https://www.redchip.com/assets/access/sxtp_access

• LBSR: https://www.redchip.com/assets/access/lbsr_access

In an exclusive interview, Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company’s mission to combat infectious diseases with innovative, small-molecule therapeutics. Dow highlights the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial developed with the U.S. Army, and its expanding commercial footprint in the U.S. He also outlines 60 Degrees Pharmaceuticals’ strategy to repurpose tafenoquine for other serious infectious diseases, including babesiosis-a growing tick-borne illness with tens of thousands of new U.S. cases annually. With two potentially pivotal clinical trials underway, a third study in the final planning stages, and a strong foundation of IP, regulatory experience, and institutional support, 60 Degrees Pharmaceuticals is advancing a cost-effective, scalable model for addressing unmet needs in global infectious disease treatment.

Pete O’Heeron, Chairman of Liberty Star, and Liberty Star board member Gerardo King, appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to highlight the Company’s dual-track strategy targeting high-grade gold and large-scale copper-gold mineralization in Arizona. They discuss recent bonanza-grade assay results from the Red Rock Canyon Gold Project, where surface samples have returned values as high as 107.5 g/t gold, and the validation of a porphyry copper system at the Hay Mountain Project through Liberty Star’s 2024 drill campaign. With gold prices near all-time highs and copper demand surging amid global electrification, Liberty Star is actively pursuing a joint venture to accelerate project development. The company’s experienced leadership and strategic positioning in one of North America’s most prolific mining regions underscore its potential to unlock significant value through near- and long-term exploration success.

SXTP and LBSR are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA^® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

About Liberty Star
Liberty Star Uranium & Metals Corp. (OTCQB:LBSR), d/b/a Liberty Star Minerals, is an Arizona-based mineral exploration company engaged in the acquisition, exploration, and development of mineral properties in Arizona and the southwest USA. Currently, the company controls properties that are located over what management considers some of North America’s richest mineralized regions for copper, gold, silver, molybdenum (moly), and associated metals. The Company’s premiere property is the Hay Mountain property (exploration stage) for porphyry copper, gold, moly and other commercially important minerals. Specific targets have been selected to explore for near-surface and deep-seated ore bodies, of which there are numerous analogs nearby. Contiguous with the primary Hay Mountain porphyry exploration target, and part of the overall Hay Mountain property, is an increasingly attractive area of exploration stage gold mineralization denominated Red Rock Canyon. Red Rock Canyon exhibits what we believe are extensive, promising hydrothermal associated gold-bearing structures that are documented in historical public and Company records. View numerous geoscientific reports on our website. The Hay Mountain & Red Rock Canyon properties are in Cochise County (southeast) Arizona, USA.

Follow Liberty Star Minerals on Facebook, LinkedIn & [X]Twitter

About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip’s products and services, please visit: https://www.redchip.com/corporate/investor_relations

“Discovering Tomorrow’s Blue Chips Today”™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com

SOURCE: RedChip Companies, Inc.

View the original press release on ACCESS Newswire

Click here to register

SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company’s founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern on Tuesday, June 10, 2025, as part of Lytham Partners’ spring 2025 Spotlight Series. The discussion will focus on Jaguar’s ongoing efforts to further its orphan disease development programs.

Participation Instructions for Jaguar Health’s Virtual Fireside Chat During Lytham Partners Spring 2025 Spotlight Series

When: Tuesday, June 10, 2025 from 9:00 – 10:00 AM Eastern

Where: Online (Click Here). The fireside chat will also be available for replay following the event.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Jaguar management will participate in a virtual fireside chat June 10, 2025 as part of Lytham Partners’ spring 2025 Spotlight Series. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline

83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS)

9.1 point average rVCSS improvement among the clinically meaningful benefit cohort

Subjects experienced a median 74% improvement in leg pain

Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators

A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025

Company to host live webcast with presenting Principal Investigator, today, June 6^th at 11:20 AM ET / 10:20 AM CT – Access the Webcast Here

IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6^th at 11:20 AM ET / 10:20 AM CT (details below).

Key interim two-year follow-up data being presented at VAM25 include:

• 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).

• 9.1 point average rVCSS improvement among the responder cohort.

• A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).

• Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size.

• Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).

• Among the subjects (n=30), a 100% valve patency rate.

All values were calculated comparing each patient’s baseline levels to the reported values at the patient’s 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases.

“These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options,” said Robert Berman, enVVeno Medical’s Chief Executive Officer. “Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option.”

Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, “Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve” today at VAM 2025.

The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025.

Webcast Details

The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, envveno.com, and will be archived for 90 days.

About CVI

Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company’s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

Clear Start Tax Explains How Divorced Taxpayers Can Escape IRS Liability for a Former Spouse’s Mistakes

IRVINE, CA / ACCESS Newswire / June 6, 2025 / Divorce can be complicated enough without the added stress of IRS debt. Yet every year, countless divorced Americans are shocked to discover they’re on the hook for a former spouse’s tax liabilities – often for mistakes they didn’t know about. According to Clear Start Tax, a leading national tax resolution firm, the IRS’s Innocent Spouse Relief program can offer a powerful – and often overlooked – solution.

When Divorce Leaves Taxpayers Facing a Former Spouse’s Mistakes

Many taxpayers assume that a divorce decree automatically separates their financial obligations. But under joint tax returns, the IRS can pursue either spouse for the full amount owed, including taxes, penalties, and interest. That means years after a divorce, one spouse may face wage garnishment, bank levies, or collection notices for a tax bill they had no role in creating.

“We’ve worked with clients blindsided by IRS letters years after their divorce,” said the Head of Client Solutions at Clear Start Tax. “Innocent Spouse Relief can be a lifeline in these cases – but most people don’t even realize it exists.”

Who Qualifies for Innocent Spouse Relief?

Clear Start Tax explains that the IRS looks at several key factors when reviewing Innocent Spouse claims:

• The tax understatement was due to the other spouse’s error (such as unreported income or inflated deductions).

• The innocent spouse didn’t know, and had no reason to know, about the issue at the time.

• Holding the innocent spouse liable would be unfair or create hardship.

• The innocent spouse applies within the IRS’s filing window (generally two years from first collection notice).

Why the Right Approach Is Essential for Approval

While the program offers powerful protection, Clear Start Tax emphasizes that success depends on a careful application and thorough documentation. Missing deadlines, submitting incomplete paperwork, or misunderstanding eligibility rules can lead to denial, leaving taxpayers exposed to the full debt.

“Innocent Spouse Relief isn’t just a form-it’s a carefully built case,” said the Head of Client Solutions at Clear Start Tax. “We work closely with our clients to present the strongest possible application, so they can move forward without being burdened by a former partner’s tax mistakes.”

How Clear Start Tax Helps Divorced Taxpayers Regain Control

Clear Start Tax offers a hands-on, strategic approach to Innocent Spouse claims and other tax resolution programs:

• Comprehensive case reviews to assess eligibility and strengthen claims

• Detailed preparation of IRS applications with supporting evidence

• Direct IRS communication and negotiation on the client’s behalf

• Post-resolution guidance to maintain compliance and peace of mind

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / June 6, 2025 / Eskay Mining Corp. (“Eskay” or the “Company”) (TSXV:ESK)(OTC PINK:ESKYF) (Frankfurt:KN7) (WKN: AOYDPM) is pleased to announce Eskay’s prospecting team will be on the ground later this month to explore the extent of the high-grade veins as well as the length of the overall mineralized trend discovered last season at the C10- Vermillion-Ted Morris (TM), trend situated in the southern portion of the Company’s 100% controlled Consolidated Eskay project.

Mac Balkam C.E.O. & President commented “Last year’s high-grade assays of as much as 205 g/t of gold, collected from outcroppings veins occurring along the 4km of the C-10 -Vermillion-Ted Morris (TM) belt, represents an exciting new discovery on our Consolidated Eskay project. Our 2025 goal is simple…… put some size to this trend and develop a drill strategy to test it’s potential. We believe a well-targeted late season drill program will show that this is a significant new discovery “

In early July, Eskay’s team will focus on the highest potential drill target, along a 210 m. zone where high grade samples were collected at Vermillion in 2024. The goal will be to expand the overall length of the strike of this zone and identify potential drill sites for late 2025. The Ted Morris and Big Red Zone located approximately 2km east of Vermillion returned rock chip assays of over 200 g/t gold in 2024. This area is considered a second high-quality target for drilling. The team will determine to what extent Vermillion and TM zones are connected and if the trend extends westward to Red Lightening.

Balkam speaking about this possibility said, “We are confident the Vermillion trend will prove to be an important gold discovery and are intrigued with the potential for this zone to become much larger. This area is a mere 9 km to the west of Newmont’s Valley of the Kings – Brucejack Mine, making this discovery all the more exciting. “

For more detail on the 2024 results at Vermillion and the TM Zone follow https://eskaymining.com/news/news-releases/eskay-minings-boots-on-the-ground-campaign-yiel-9576.

To watch the video of Dr Hennigh outlining the potential in the Vermillion -TM zone follow https://youtu.be/ju8gRF2gN9A

Dr. Quinton Hennigh, P. Geo., a Director of the Company and its technical adviser, a qualified person as defined by National Instrument 43-101, has reviewed and approved the technical contents of this news release.

About Eskay Mining Corp:

Eskay Mining Corp (TSX-V:ESK) is a TSX Venture Exchange listed company, headquartered in Toronto, Ontario. Eskay is an exploration company focused on the exploration and development of precious and base metals along the Eskay rift in a highly prolific region of northwest British Columbia known as the “Golden Triangle,” 70km northwest of Stewart, BC. The Company currently holds mineral tenures in this area comprised of 177 claims (52,600 hectares).

All material information on the Company may be found on its website at www.eskaymining.com and on SEDAR+ at www.sedarplus.com.

For further information, please contact:

Mac Balkam
T: 416 907 4020
President & Chief Executive Officer
E: Mac@eskaymining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such as actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements

SOURCE: Eskay Mining Corp.

View the original press release on ACCESS Newswire

JACKSONVILLE, FL / ACCESS Newswire / June 6, 2025 / GEE Group Inc. (NYSE American:JOB) together with its subsidiaries (collectively referred to as the “Company,” “GEE Group,” “our” or “we”), a provider of professional staffing services and human resource solutions, today announced that, effective June 2, 2025, it has completed the successful sale of Triad, its Light Industrial Division, to Armada Staffing Group (“Armada”), a division of Ohio based Reliable Staffing Resources (“Reliable”), led by the Gasbarro family. This strategic transaction marks a continued focus by GEE Group on its professional staffing and human resources solutions specialty service offerings, in verticals comprised of Information Technology, Engineering, Finance and Accounting, Office Support and Health Care.

Under the terms of the sale and purchase agreement, Reliable acquired substantially all of the the operating business assets of GEE Group’s Triad Light Industrial Division for cash and other consideration. As part of the sale, nearly all employees from the Light Industrial Division have transitioned to and will join the workforce of Armada, ensuring outstanding customer service and continuity for both clients and candidates. Notably, Deborah Santora, President of Triad, will continue to lead the operations in the Northeast Ohio market, supported by her experienced team that will join her at Armada. Other terms of the transaction were not disclosed. The Company previously communicated that the Light Industrial Division business segment was a “discontinued operation” and reported it as such in its most recent Form 10-Q filed with the SEC.

“We are confident that Armada Staffing Group, under the leadership of the Gasbarro family, will provide strong direction and make investments that will benefit the Light Industrial Division,” said Alex Stuckey, Chief Operating Officer of GEE Group. Stuckey further commented, “All of us at GEE Group thank Debbie and her team for their many years of service and outstanding contributions and wish them continued success in this next chapter.” Derek Dewan, Chairman and Chief Executive Officer of GEE Group stated, “Our Company will continue to provide outstanding customer service and expand our service offerings in the professional services verticals that we operate in and GEE Group will continue to pursue the strategic initiatives that align with our capital allocation strategy and internal and acquisition growth plans.”

About Armada Staffing Group / Reliable Staffing Resources

Armada Staffing Group is a division of Ohio based Reliable Staffing Resources, a family-owned and operated firm led by the Gasbarro family. With deep roots in the staffing industry, the company is recognized for its client-focused approach and commitment to workforce excellence.

About GEE Group

GEE Group Inc. is a provider of specialized staffing solutions and is the successor to employment offices doing business since 1893. The Company operates in two industry segments, providing professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and commercial staffing services through the names of Access Data Consulting, Agile Resources, Ashley Ellis, General Employment, Hornet Staffing, Omni-One, Paladin Consulting and Triad. Also, in the healthcare sector, GEE Group, through its Scribe Solutions brand, staffs medical scribes who assist physicians in emergency departments of hospitals and in medical practices by providing required documentation for patient care in connection with electronic medical records (EMR). Additionally, the Company provides contract and direct hire professional staffing services through the following SNI brands: Accounting Now®, SNI Technology®, Legal Now®, SNI Financial®, Staffing Now®, SNI Energy®, and SNI Certes.

Forward-Looking Statements Safe Harbor

In addition to historical information, this press release contains statements relating to possible future events and/or the Company’s future results (including results of business operations, certain projections, future financial condition, pro forma financial information, and business trends and prospects) that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” created by those sections. The statements made in this press release that are not historical facts are forward-looking statements that are predictive in nature and depend upon or refer to future events. These forward-looking statements include without limitation information relating to our intended share repurchases, the amount and timing of share repurchases, the possibility that the share repurchase program may be discontinued or suspended, anticipated cash flow generation and expected shareholder benefits. Such forward-looking statements often contain, or are prefaced by, words such as “will”, “may,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “pro forma”, “estimates,” “aims,” “believes,” “hopes,” “potential,” “intends,” “suggests,” “appears,” “seeks,” or variations of such words or similar words and expressions. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and, consequently, as a result of a number of factors, the Company’s actual results could differ materially from those expressed or implied by such forward-looking statements. Certain factors that might cause the Company’s actual results to differ materially from those in the forward-looking statements include, without limitation: (i) the loss, default or bankruptcy of one or more customers; (ii) changes in general, regional, national or international economic conditions; (iii) an act of war or terrorism, industrial accidents, or cyber security breach that disrupts business; (iv) changes in the law and regulations; (v) the effect of liabilities and other claims asserted against the Company including the failure to repay indebtedness or comply with lender covenants including the lack of liquidity to support business operations and the inability to refinance debt, failure to obtain necessary financing or the inability to access the capital markets and/or obtain alternative sources of capital; (vi) changes in the size and nature of the Company’s competition; (vii) the loss of one or more key executives; (viii) increased credit risk from customers; (ix) the Company’s failure to grow internally or by acquisition or the failure to successfully integrate acquisitions; (x) the Company’s failure to improve operating margins and realize cost efficiencies and economies of scale; (xi) the Company’s failure to attract, hire and retain quality recruiters, account managers and salesmen; (xii) the Company’s failure to recruit qualified candidates to place at customers for contract or full-time hire; (xiii) the adverse impact of geopolitical events, government mandates, natural disasters or health crises, force majeure occurrences, global pandemics such as the deadly “coronavirus” (COVID-19) or other harmful viral or non-viral rapidly spreading diseases and such other factors as set forth under the heading “Forward-Looking Statements” in the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q and in the Company’s other filings with the Securities and Exchange Commission (SEC). More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company is under no obligation to (and expressly disclaims any such obligation to) and does not intend to publicly update, revise, or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Contact:

GEE Group Inc.
Kim Thorpe
630.954.0400
invest@geegroup.com

SOURCE: GEE Group Inc.

View the original press release on ACCESS Newswire

New Segment “BestETFs.com” Kicks Off Filming Next Week Highlighting Top Performing ETFs

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / New to The Street, one of the longest-running national business TV brands, proudly announces it has signed MUSQ ETF to a multi-part media partnership. This campaign will include exclusive long-form interviews, national TV commercial placements, earned media features, and full social and digital distribution.

The series will anchor the launch of BestETFs.com, a new segment designed to spotlight the most innovative and growth-oriented ETFs in today’s market. Filming begins next week from the iconic NYSE floor and other financial landmarks, with MUSQ ETF featured prominently in the rollout. BestETFs.com will officially launch in July 2025, offering a dedicated media destination for ETF thought leadership, investor discovery, and brand visibility.

MUSQ ETF, which captures the growth of the global music and entertainment economy, has gained attention for its focused exposure to high-potential sectors such as streaming, live events, and music tech.

Vince Caruso, Co-Founder and CEO of New to The Street, commented:

“We believe ETFs like MUSQ are shaping the next era of portfolio innovation-and our media platform is uniquely positioned to support both the ETF managers and the underlying companies they invest in.

With over 2.5 million YouTube subscribers, national broadcasts on Fox Business and Bloomberg, and a growing outdoor footprint in NYC, we’re giving ETF brands and their top holdings a unified media engine that drives awareness, credibility, and investor attention at scale.”

The BestETFs.com segment will feature top-performing ETFs, with targeted media delivery to financial audiences, institutional allocators, and retail investors across all platforms.

About MUSQ ETF
Exchange Traded Concepts Trust – MUSQ Global Music Industry Index ETF (NASDAQ:MUSQ) is an exchange-traded fund launched and managed by Exchange Traded Concepts, LLC. The fund provides targeted exposure to the global music industry, investing in public companies across music streaming, content and distribution, live events and ticketing, as well as music-related equipment and technology. MUSQ uses a full replication strategy to track the MUSQ Global Music Industry Index, which aims to capture the performance of key music industry segments worldwide. Formed on July 6, 2023, and domiciled in the U.S., the fund seeks to deliver total return performance that corresponds generally to the MUSQ Global Music Industry Total Return Index (TR USD).

About New to The Street
Founded in 2009, New to The Street has grown into a dominant force in business media, broadcasting weekly on Fox Business and Bloomberg Television as sponsored programming. The company specializes in long-form interviews with public and private company CEOs, institutional fund managers, and innovators from the financial, biotech, tech, and energy sectors. With over 2.53 million YouTube subscribers, the platform also offers nationwide billboard advertising, earned media on ABC, NBC, and CBS affiliates, and international syndication-reaching over 245 million households weekly. In 2025, the brand launched BestETFs.com, a dedicated segment and digital destination highlighting elite ETFs and their top portfolio companies. BestETFs.com will officially go live in July 2025.

Media Contact:
Monica Brennan
New to The Street
Email: monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / June 5, 2025 / New to The Street, the nation’s leading multi-platform financial news show, today announced it has signed a 12-part media partnership with NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company focused on life-saving therapies for patients with suicidal depression, PTSD, and chronic pain.

The partnership will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, providing updates from the front lines of biotech innovation. As part of the comprehensive campaign, New to The Street will also produce earned media placements on ABC, NBC, and CBS affiliates, a full suite of nationally aired TV commercials, and premium outdoor billboard exposure in Times Square and throughout the NYC Financial District.

“Our mission has always been to save lives with science,” said Jonathan Javitt, MD, MPH, Founder and CEO of NRx Pharmaceuticals. “Partnering with New to The Street enables us to share the life-saving potential of NRX-101 and our broader pipeline with a national audience, at a pivotal moment in our regulatory and commercial path.”

“We are proud to bring NRX’s critical work to our global audience,” said Vince Caruso, Co-Founder and CEO of New to The Street. “This series will spotlight a company on the front lines of neuroscience and public health, and exemplifies our commitment to covering stories that matter-with scale, credibility, and impact.”

The series begins airing later this month on Fox Business and Bloomberg Television as sponsored programming, reaching more than 245 million homes weekly across the U.S. and Middle East. Episodes will also stream on New to The Street’s YouTube channel, which now exceeds 2.5 million subscribers, and be supported by billboard takeovers in Times Square and full media amplification through the NewsOut™ and AccreditedEvents.com platforms.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders. Its lead investigational drug, NRX-101, has been granted FDA Breakthrough Therapy and Fast Track Designation for suicidal bipolar depression. The company is also pursuing accelerated approval for preservative-free IV ketamine (NRX-100) and advancing additional treatments for PTSD, chronic pain, and UTIs. Learn more at www.nrxpharma.com.

About New to The Street

New to The Street is a leading branded content TV series that features innovative public and private companies on national television, including Fox Business and Bloomberg Television. With more than 2.52 million YouTube subscribers, a reach of 245 million TV households, and a powerful outdoor media footprint, the platform offers unmatched exposure across digital, television, and out-of-home channels. Learn more at www.NewToTheStreet.com.

Media Contact:
Monica Brennan
PR Coordinator, New to The Street
Email: Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

SURREY, BRITISH COLUMBIA / ACCESS Newswire / June 5, 2025 / Consumer Choice Award is pleased to announce the 2025 award recipients in the Surrey region. These businesses have been meticulously selected through independent market research, reflecting their commitment to excellence and unparalleled service in their city. Consumer Choice Award celebrates those who have consistently set the benchmark for quality and customer satisfaction. Congratulations to the 2025 Surrey Consumer Choice Award Winners.

SURREY AWARD RECIPIENTS

Apna Pest Control Surrey Category: Pest Control www.apnapestcontrol.ca		BSL Security Category: Security Guard Services www.bslsecurityservices.com
Coleman Technologies Category: Computer Consultants www.colemantechnologies.com		Complete Accounting Solutions Category: Accountant – Small Business www.completeaccounting.ca
Doctoraujla Environmental Consultants Category: Environmental Consultant www.doctoraujla.com		Dreams Gymnastics Inc. Category: Gymnastics School www.dreamsgymnastics.ca
Forward Mind Counselling Category: Counselling Services www.forwardmindcounselling.com		Gamdur Chinese Medicine & Acupuncture Clinic Inc. Category: Acupuncture www.gamdurchinesemedicineacupuncture.com
Greystone Blinds Category: Window Treatments Coverings www.greystoneblinds.ca		HD Top Building Maintenance Category: Janitorial Services www.hdtopbuilding.com
Jose & Co. Custom Jewellers Category: Jewellers www.joseandco.ca		La Belle Fleur Floral Boutique Category: Florist www.labellefleursurrey.com
Lasik MD Category: Laser Vision Correction www.lasikmd.com/clinics/vancouver		MNP Ltd Category: Licensed Insolvency Trustee www.mnpdebt.ca/en/offices/surrey
PictureAve. Photobooth Category: Photo Booth Rentals www.pictureavephotobooth.com		Quay Pacific Property Management Ltd Category: Property Management www.quaypacific.com
Rachel Yoon Photography Category: Photographer – Baby and Child www.rachelyoonphotography.com		Railing Experts Category: Stairs & Railings www.railingexperts.ca
Set Canada Immigration Category: Immigration Consulting www.setcanadaimmigration.com		Shadow Investigations Ltd Category: Investigators www.shadowinvestigationsltd.ca
SM Lighting & Bath Design Category: Lighting Store www.savemorelighting.ca		Synergy Rehab Category: Physiotherapists www.synergyrehabilitation.ca
Taste of Lahore Restaurant Category: Restaurants – Pakistani www.tasteoflahore.easytodine.com		VE Stone Ltd. Category: Countertops www.vestone.ca
Versa Homes Category: Home Builders www.versahomes.com		Walnut Grove School Of Music & Dance Category: School – Dance www.musicanddance.org
Westgroup Financial Management Inc Category: Financial Planning www.westgroupfinancial.com		Woodhouse Realty Category: Residential Real Estate Brokerage www.woodhouserealty.com

Learn more about 2025 Surrey Consumer Choice Award Winners HERE.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

NORTH VANCOUVER, BC / ACCESS Newswire / June 5, 2025 / Consumer Choice Award is pleased to announce the 2025 award recipients in the North Vancouver region. These businesses have been meticulously selected through independent market research, reflecting their commitment to excellence and unparalleled service in their city. Consumer Choice Award celebrates those who have consistently set the benchmark for quality and customer satisfaction. Congratulations to the 2025 North Vancouver Consumer Choice Award Winners.

NORTH VANCOUVER AWARD RECIPIENTS

Andrew Reid Category: Residential Real Estate www.haddenproperties.com		Avita Health & Massage Therapy Center Category: Massage Therapy www.avitahealth.ca
Co-Operators – North Vancouver (Peiman Javdan Investments & Insurance Services Ltd) Category: Business/Home/Life and Auto Insurance www.local.cooperators.ca/javdan-investments-insurance-en		Dr. Mandana Edalati, ND Wellness Naturopathic Centre Category: Naturopathic Medicine www.wellnessnaturopathic.com
Ellis Moving & Storage Ltd. Category: Moving Companies www.ellismoving.com		Foodie Fit Category: Caterers www.foodiefit.ca
Heilman Renovations Category: North Shore Renovation Contractor www.heilmanrenovations.ca		Hollyburn Eye Clinic Category: Opticians/Optometrists www.hollyburneyeclinic.com
Inspired Architecture Category: Architecture Firm www.inspiredarchitecture.ca		Mermi Music Academy Category: School – Music www.mermimusic.ca
MNP Ltd Category: Licensed Insolvency Trustee www.mnpdebt.ca/en/offices/north-vancouver		Pink Plumbing Group Category: Plumbing Contractor www.pinkplumbing.ca
Prime Credit Solution Category: Credit Debt Counselling Service www.primecreditsolution.com		Quantum Hearing Clinic Category: Hearing Services www.quantumhearing.com
Selfcrete Concrete Floor Levelling Category: Concrete Levelling www.selfcrete.net		Vancouver TESOL Training Center Category: Language Schools www.vttcenters.ca
West Vancouver Foot Clinic Category: Podiatrists www.westvanfootclinic.com

Learn more about 2025 North Vancouver Consumer Choice Award Winners HERE.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire